Kardiale elektrische Device-Therapie bei Herzinsuffizienz

Eine chronische Herzinsuffizienz stellt die Endstrecke von Erkrankungen mit kardialer Beteiligung dar und limitiert Prognose sowie Lebensqualität des Patienten. Therapeutisch kann der Verlauf durch kardiale implantierbare elektrische Devices (CIEDs) günstig beeinflusst werden. Die differenzierten Einsatzmöglichkeiten von CIEDs werden im Folgenden dargestellt.

Abstract

Heart failure is one of the most common reasons for inpatient treatment and one of the most common causes of death in Germany. In addition to coronary heart disease (ischemic cardiomyopathy, ICM), there are also numerous other diseases as non-ischemic cardiomyopathy, NICM. Chronic heart failure is the final stage of diseases with cardiac involvement and limits the prognosis and quality of life of patients. The course can be favorably influenced by cardiac implantable electrical devices (CIEDs). There are different uses of CIEDs which are shown in this article.

Schlüsselwörter

Herzinsuffizienz - Herzschrittmacher - elektrische Device-Therapie

Key words

heart failure - pacemaker - electrical device therapy

• Literatur

• 1 Kusumoto FM, Schoenfeld MH, Barrett C. et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2019; 140: e382-e482
• 2 Brignole M, Auricchio A, Baron-Esquivias G. et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Europace 2013; 15: 1070-118
• 3 Priori SG, Blomström-Lundqvist C, Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015; 36: 2793-2867
• 4 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2129-2200
• 5 Seferovic PM, Ponikowski P, Anker SD. et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 1169-1186
• 6 Merchant FM, Mittal S. Pacing-induced cardiomyopathy. J Cardiovasc Electrophysiol 2020; 31: 286-292
• 7 Israel CW, Tribunyan S, Richter S. Indications for His bundle and left bundle branch pacing. Herzschr Elektrophys 2020; 31: 135-143
• 8 Zabel M, Willems R, Lubinski A. et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;
• 9 Køber L, Thune JJ, Nielsen JC. et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375: 1221-1230
• 10 Schrage B, Uijl A, Benson L. et al. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry. Circulation 2019; 140: 1530-1539
• 11 Kusumoto FM, Calkins H, Boehmer J. et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation 2014; 130: 94-125
• 12 Chung ES, Katra RP, Ghio S. et al. Cardiac Resynchronization Therapy May Benefit Patients With Left Ventricular Ejection Fraction >35%: A PROSPECT Trial Substudy. Eur J Heart Fail 2010; 12 (06) 581-587
• 13 Ruschitzka F, Abraham WT, Singh JP. et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369: 1395-1405
• 14 Stockburger M, Moss AJ, Klein HU. et al. Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. Clin Res Cardiol 2016; 105: 944-952
• 15 Daubert JC, Saxon L, Adamson PB. et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 2012; 14: 1236-1286
• 16 Van Gelder BM, Scheffer MG, Meijer A. et al. Transseptal endocardial left ventricular pacing: an alternative technique for coronary sinus lead placement in cardiac resynchronization therapy. Heart Rhythm 2007; 4: 454-460
• 17 Butter C, Fehrendt S, Möller V. et al. Sondenlose endokardiale linksventrikuläre Stimulation WiSE™ CRT-System: Alternative zu herkömmlichen Verfahren. Herzschr Elektrophys 2018; 29: 340-348
• 18 Whellan DJ, Ousdigian KT, Al-Khatib SM. et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol 2010; 55: 1803-1810
• 19 Hindricks G, Taborsky M, Glikson M. et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014; 384: 583-590
• 20 Abraham WT, Adamson PB, Bourge RC. et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377: 658-666
• 21 Kuschyk J, Rudic B, Liebe V. et al. Kardiale Kontraktilitätsmodulation zur Behandlung der chronischen Herzinsuffizienz. Herzschr Elektrophys 2018; 29: 369-376
• 22 Borggrefe M, Mann DL. Cardiac Contractility Modulation in 2018. Circulation 2018; 138 (24) 2738-2740
• 23 Abraham WT, Zile MR, Weaver FA. et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015; 3: 487-496
• 24 Anand IS, Konstam MA, Klein HU. et al. Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. ESC Heart Fail 2020; 7: 75-83
• 25 Zipes DP, Neuzil P, Theres H. et al. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC Heart Fail 2016; 4: 129-136
• 26 Costanzo MR, Ponikowski P, Coats A. et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. Eur J Heart Fail 2018; 20: 1746-1754